Clinical Trials at Englewood Hospital: Oncology
EHMC IRB Study #: E-11-423
Dr. Brian Kim
National Cancer Institute - SWOG
EVEREST: Everolimus for Renal Cancer Ensuing Surgical Thearpy, a Phase III Study
Patients who are at least 18 years old with confirmed renal cell carcinoma, who have undergone a full resection with negative margins, and who have not received any prior treatment.
To compare recurrence-free survival in renal carcinoma patients randomly assigned to one year of everolimus vs. one year of placebo after nephrectomy or partial nephrectomy.
Summary of procedures:
Patients will be randomized to receive either everolimus or placebo daily by mouth for nine, six-week cycles. Assessments for recurrence will be done every three cycles (18 weeks) for 54 weeks, then every 6 months for two years, then annually thereafter until recurrence Year 10, whichever occurs first.